Inhibitor Therapeutics (INTI) Payables (2012 - 2026)
Inhibitor Therapeutics' (INTI) quarterly Payables came in at $319803.0 in Q1 2026, up 771.35% YoY from $36702.0 in Q1 2025, and up 520.72% on a QoQ basis from $51521.0 in Q4 2025.
Inhibitor Therapeutics (INTI) Payables (2012 - 2026) Analysis & Trends
Inhibitor Therapeutics (INTI) has 15 years of Payables data on file, last reported at $319803.0 in Q1 2026.
- Quarterly Payables rose 771.35% year-over-year to $319803.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $319803.0 (up 771.35% YoY) and the FY2025 annual result came in at $51521.0, up 224.11% from the prior year.
- Payables rose to $319803.0 in Q1 2026, from $51521.0 in the prior quarter.
- In the past five years, Payables ranged from a high of $987877.0 in Q3 2022 to a low of $1706.0 in Q3 2024.
- A 5-year average of $233272.6 and a median of $51521.0 in 2025 frame the typical range for Payables.
- Annual changes were most pronounced in 2023 — Payables plunged 99.33% — and 2024, when it soared 2135.19%.
- Tracing INTI's Payables over 5 years: stood at $556161.0 in 2022, then sank by 93.94% to $33731.0 in 2023, then sank by 52.87% to $15896.0 in 2024, then soared by 224.11% to $51521.0 in 2025, then jumped by 520.72% to $319803.0 in 2026.
- The last three Payables figures came in at $319803.0 (Q1 2026), $51521.0 (Q4 2025), and $19646.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | 139,052.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 319,803.00 |
| Dec 31, 2025 | 51,521.00 |
| Sep 30, 2025 | 19,646.00 |
| Jun 30, 2025 | 106,249.00 |
| Mar 31, 2025 | 36,702.00 |
| Dec 31, 2024 | 15,896.00 |
| Sep 30, 2024 | 1,706.00 |
| Jun 30, 2024 | 18,803.00 |
| Mar 31, 2024 | 111,916.00 |
| Dec 31, 2023 | 33,731.00 |
| Sep 30, 2023 | 93,147.00 |
| Jun 30, 2023 | 11,750.00 |
| Mar 31, 2023 | 5,007.00 |
| Dec 31, 2022 | 556,161.00 |
| Sep 30, 2022 | 987,877.00 |
| Jun 30, 2022 | 842,880.00 |
| Mar 31, 2022 | 752,839.00 |
| Dec 31, 2021 | 611,665.00 |
| Sep 30, 2021 | 355,231.00 |
| Jun 30, 2021 | 399,251.00 |